Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M11D1 in relapsed/refractory acute myeloid leukemia
NCT05924750Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BL-M11D1 in acute myeloid leukemia (AML), sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Aug 2023; status: recruiting.
02
Drugs
BL-M11D1
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05924750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05924750.